Korify Capital

FORME, founded in 2020 and based in Los Angeles, California, offers an integrated home fitness platform that focuses on sports and fitness instruction. The company provides interactive wellness and strength training sessions, allowing customers to engage in personalized workouts from the comfort of their homes. In addition to fitness training, FORME’s health coaching services include guidance on nutrition, recovery, sleep, and various lifestyle aspects. Revenue is generated through the sale of connected fitness products, membership fees, and personal training services, positioning FORME as a comprehensive solution for individuals seeking to enhance their fitness and overall well-being.

Wonder Brands is a Latin American startup focused on partnering with successful digital brands to enhance their growth potential. The company achieves this by injecting substantial investments into its partner brands, thereby increasing their working capital, marketing capabilities, and operational resources. In addition to financial support, Wonder Brands provides expertise in areas such as technology, digital marketing, supply chain management, and administration. This comprehensive approach allows clients to better respond to consumer needs while diversifying their product offerings and expanding their target audiences. Through these strategic partnerships, Wonder Brands aims to foster significant growth for the brands it collaborates with.

Bullish Global is a new blockchain-based cryptocurrency exchange designed to combine the performance, user privacy, and compliance offered by central order book technology with the vertically integrated user benefits of decentralized finance (DeFi) market architecture.

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

NextMarkets GmbH, founded in 2014 and based in Cologne, Germany, offers an intuitive web and mobile trading platform aimed at empowering private investors in capital markets. The platform allows users to trade over 1,000 contracts for difference (CFDs) on various asset classes, including equities, foreign exchange, bonds, and commodities. Recognizing that more than 80 percent of private investors typically struggle in the stock market due to behavioral economic factors, NextMarkets provides educational resources and trading strategies to enhance users' understanding and decision-making capabilities. By focusing on sustainable trading practices, the company strives to improve the overall experience and success rate of individual investors in navigating financial markets.

ATAI Life Sciences AG is a clinical-stage biopharmaceutical company headquartered in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative treatments for mental health disorders, addressing significant unmet medical needs. ATAI employs a decentralized, technology-driven platform model to accelerate the development of therapies. Its diverse portfolio includes product candidates such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and GRX-917 (Deuterated etifoxine), among others. By pooling expertise and resources, ATAI aims to create impactful, evidence-based therapies that can transform mental health treatment. The company operates primarily in Germany and the United States.

Cambrian Biopharma is a multi-asset biotech R&D firm uniquely focused on a specific field of biomedical research: the biology of aging, also known as geroscience. We believe the future of medicine should be proactive and committed to extending our best years, not just reactive to certain diseases. As experts in the biology of age-related disease, it is our mission to assemble the world's best scientists to accelerate this paradigm shift. We are built on an emerging business model we call a "Distributed R&D Company" (or "DisCo"), partnering with academic geroscientists to build companies, conduct preclinical drug discovery, and manage clinical trials. Cambrian looks to discover and develop therapeutics that target the molecular damage that arises during aging and leads to chronic disease. Our approach is to build a diverse portfolio led by scientific rigor and data, not ego. Focusing on early-stage therapeutics, we collaborate with pioneering scientists to bring discoveries out of the lab and into the clinic as efficiently as possible. So far, we have launched 10 companies with leading geroscientists and have relationships with more than 100 geroscience-focused labs globally, translating to a toolkit for tech-transfer negotiations and rapid spinouts.

Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.

Centenara Labs is a biotechnology company that focuses on developing innovative drug therapies aimed at improving and prolonging human lifespan. Founded in 2019 and headquartered in Zug, Switzerland, the company invests in research and technologies that target age-related diseases. Centenara Labs operates as a fully integrated platform, providing a range of services including drug discovery expertise, financial support, and administrative services. Its mission is to advance scientific understanding and create effective solutions that enable individuals to experience healthier and longer lives.